Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease

Autor: Jakob A. Østergaard, Jay C. Jha, Arpeeta Sharma, Aozhi Dai, Judy S.Y. Choi, Judy B. de Haan, Mark E. Cooper, Karin Jandeleit-Dahm

Publikováno v: Østergaard, J A, Jha, J C, Sharma, A, Dai, A, Choi, J S Y, De Haan, J B, Cooper, M E & Jandeleit-Dah, K 2022, ' Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease ', Clinical Science, vol. 136, no. 2, pp. 167-180 . https://doi.org/10.1042/CS20210865
Clinical Science (London, England : 1979)

Activation of nucleotide-binding oligomerization domain-like receptor pyrin domain containing 3 (NLRP3) inflammasome has been reported in diabetic complications including diabetic kidney disease (DKD). However, it remains unknown if NLRP3 inhibition

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecb74c1c6696820a6519eb2f38a2726e
https://doi.org/10.1042/cs20210865

Extended Prophylactic Effect of N-tert-Butyl-α-phenylnitron against Oxidative/Nitrosative Damage Caused by the DNA-Hypomethylating Drug 5-Azacytidine in the Rat Placenta

Autor: Nikola Sobočan, Marta Himelreich-Perić, Ana Katušić-Bojanac, Jure Krasić, Nino Sinčić, Željka Majić, Gordana Jurić-Lekić, Ljiljana Šerman, Andreja Marić, Davor Ježek, Floriana Bulić-Jakuš

Publikováno v: International Journal of Molecular Sciences; Volume 23; Issue 2; Pages: 603
International Journal of Molecular Sciences, Vol 23, Iss 603, p 603 (2022)
International Journal of Molecular Sciences

Antioxidant N-tert-Butyl-α-phenylnitron (PBN) partly protected embryos from the negative effects of a DNA demethylating drug 5-azacytidine during pregnancy. Our aim was to investigate PBN’s impact on the placenta. Fischer rat dams were treated on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fdb5992b1798da16989b4cf40783133

Chronic fatigue syndrome (CFS): Suggestions for a nutritional treatment in the therapeutic approach

Autor: Joeri J Pen, Maryam Dadar, Geir Bjørklund, Salvatore Chirumbolo, Jan Aaseth

Publikováno v: Biomedicine & Pharmacotherapy, Vol 109, Iss, Pp 1000-1007 (2019)
Biomedicine and Pharmacotherapy

Chronic fatigue syndrome (CFS) is known as a multi-systemic and complex illness, which induces fatigue and long-term disability in educational, occupational, social, or personal activities. The diagnosis of this disease is difficult, due to lacking a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1184d271169c117c18adaa7d83dc870f
https://doi.org/10.1016/j.biopha.2018.10.076

The effect of dietary phytochemicals on nuclear factor erythroid 2-related factor 2 (Nrf2) activation: a systematic review of human intervention trials

Autor: Stephen J. Bailey, Stuart P. Cocksedge, Kelly A Bowden Davies, Tom Clifford, Jarred P Acton

Publikováno v: Molecular Biology Reports

We conducted a systematic review of human trials examining the effects of dietary phytochemicals on Nrf2 activation. In accordance with the PRISMA guidelines, Medline, Embase and CAB abstracts were searched for articles from inception until March 202

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5e3c54cceeeaf75c881b478ce279ff8
https://e-space.mmu.ac.uk/627935/

Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events

Autor: Cecilia Carubbi, Elena Masselli, Riccardo R.C. Bonadonna, Giuliana Gobbi, Anna Solini, Alessandra Dei Cas, Giulia Pozzi, Valentina Spigoni, Federica Fantuzzi

Publikováno v: Cardiovascular Diabetology
Cardiovascular diabetology, 19 (1
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-15 (2020)

The clear evidence of cardiovascular benefits in cardiovascular outcome trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes might suggest an effect on atherosclerotic plaque vulnerability and/or thrombosis, in which myeloi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db1d2ff06039e7052bef6fbb6960c97d
http://europepmc.org/articles/PMC7140327